Brief Title
Adenoid Cystic Carcinoma and Carbon Ion Only Irradiation
Official Title
Adenoid Cystic Carcinoma and Carbon Ion Only Irradiation
Brief Summary
Adenoid cystic tumors are rare tumors of the head and neck region. Despite their slow growth, re-irradiation is often necessary due to the high metastatic risk. Patients are usually irradiated with photons or, as here at the Heidelberg University Hospital, with a combination of carbon ions and photons. So far, there is no data from Europe available for the sole irradiation with carbon ions. The present ACCO (Adenoid Cystic Carcinoma and Carbon ion Only irradiation) study, a prospective, open-label, phase II, single-arm, investigator-initiated study, will therefore investigate the sole radiotherapy of carbon ions in this tumor entity. Irradiation is applied - significantly shorter than the combination therapy - in about 4 weeks (22 fractions); patients are followed up for further 5 years after the start of therapy. Carbon ions alone are expected to increase local tumor control rates from 60% to 70% after 5 years (primary objective criterion of this study). In order to reject the null hypothesis with a power of 80% and a significance level of 5%, 175 patients are included (including a drop-out rate of 15%). Secondary objective criteria are progression-free survival, overall survival, acute and late toxicity, and quality of life.
Study Phase
Phase 2
Study Type
Interventional
Primary Outcome
Freedom from loco-regional progression
Secondary Outcome
Progression-free survival
Condition
Adenoid Cystic Carcinoma
Intervention
Carbon ion irradiation
Study Arms / Comparison Groups
Carbon Ion irradiation
Description: 22 x 3 Gy(RBE) Carbon Ions
Publications
* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.
Recruitment Information
Recruitment Status
Radiation
Estimated Enrollment
314
Start Date
December 15, 2019
Completion Date
January 1, 2032
Primary Completion Date
January 1, 2032
Eligibility Criteria
Inclusion Criteria: - Histologically confirmed adenoid cystic carcinoma in the head and neck area - Indication for irradiation: - non-operable or - R1/R2 resected or - perineural sheat invasion (Pn+) or - pT3/pT4 - Informed consent - KI > 60% or ECOG 0/1 (minimum: self-sufficiency, normal activity or work not possible) - Age 18-80 years Exclusion Criteria: - rejection of the study by the patient - Patient is not able to consent - Stage IV (distant metastases), except lung metastases < 1cm - lymph node involvement (clinical or pathological) - Previous radiotherapy in the head and neck area - Active medical implants for which there is no ion radiation authorization at the time of treatment (e.g., cardiac pacemaker, defibrillator, ...) - Contraindication to MR imaging - Simultaneous participation in another clinical study that could influence the outcome of this study or the other study - Pregnancy
Gender
All
Ages
18 Years - 80 Years
Accepts Healthy Volunteers
No
Contacts
Klaus Herfarth, Prof. Dr., +49 6221 56 8201, [email protected]
Location Countries
Germany
Location Countries
Germany
Administrative Informations
NCT ID
NCT04214366
Organization ID
ACCO
Responsible Party
Principal Investigator
Study Sponsor
Heidelberg University
Study Sponsor
Klaus Herfarth, Prof. Dr., Principal Investigator, University Hospital Heidelberg
Verification Date
August 2021